Related Experiment Video
Updated: Jul 15, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Management of chronic hepatitis C.
T Asselah1, N Boyer, M P Ripault
1Service d'Hépathologie and INSERM U 773, University of Paris VII, Beaujon Hospital, Clichy, France.
Minerva Gastroenterologica E Dietologica
|April 7, 2007
Summary
Chronic hepatitis C can lead to liver cirrhosis and cancer. Current treatments like pegylated interferon and ribavirin offer a sustained virologic response in about 55% of patients, improving outcomes.
Area of Science:
- Hepatology
- Virology
- Gastroenterology
Background:
- Chronic hepatitis C is a leading cause of liver cirrhosis, hepatocellular carcinoma, and liver transplantation.
- Disease progression, marked by fibrosis, dictates patient prognosis and management strategies.
- Predicting individual fibrosis progression remains challenging.
Purpose of the Study:
- To review the natural history of chronic hepatitis C.
- To identify factors influencing fibrosis progression.
- To discuss current and future treatment options and their predictive factors.
Main Methods:
- Literature review on chronic hepatitis C natural history and fibrosis.
- Analysis of treatment outcomes for pegylated alpha interferon and ribavirin combination therapy.
- Discussion of prognostic indicators and therapeutic strategies.
Main Results:
- Liver biopsy is the gold standard for assessing fibrosis severity and guiding treatment.
- Combination therapy with pegylated interferon and ribavirin achieves a sustained response in approximately 55% of cases.
- Sustained virologic response is associated with histological improvement and reduced risk of cirrhosis and cancer.
Conclusions:
- Understanding hepatitis C's natural history and fibrosis progression is crucial for patient management.
- Current antiviral treatments offer significant benefits, with sustained responses being long-lasting.
- Close patient monitoring and exploration of new therapeutic agents are essential.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...